170 related articles for article (PubMed ID: 11592782)
1. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.
Pavillard V; Kherfellah D; Richard S; Robert J; Montaudon D
Br J Cancer; 2001 Sep; 85(7):1077-83. PubMed ID: 11592782
[TBL] [Abstract][Full Text] [Related]
2. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
Ciesielski MJ; Fenstermaker RA
J Neurooncol; 1999 Feb; 41(3):223-34. PubMed ID: 10359142
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
Huet S; Schott B; Robert J
Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
[TBL] [Abstract][Full Text] [Related]
5. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
Bertrand R; O'Connor PM; Kerrigan D; Pommier Y
Eur J Cancer; 1992; 28A(4-5):743-8. PubMed ID: 1326304
[TBL] [Abstract][Full Text] [Related]
7. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro.
Maleklou N; Allameh A; Kazemi B
In Vitro Cell Dev Biol Anim; 2016 Dec; 52(10):989-1000. PubMed ID: 27503515
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
12. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
13. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
15. 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Dwarakanath BS; Khaitan D; Ravindranath T
Cancer Biol Ther; 2004 Sep; 3(9):864-70. PubMed ID: 15254410
[TBL] [Abstract][Full Text] [Related]
16. Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Matsumoto Y; Fujiwara T; Nagao S
J Neurooncol; 1995; 23(1):1-8. PubMed ID: 7623066
[TBL] [Abstract][Full Text] [Related]
17. Long-term exposure to irinotecan reduces cell migration in glioma cells.
Al-Ghafari AB; Punjaruk W; Storer LC; Carrier DJ; Hussein D; Coyle B; Kerr ID
J Neurooncol; 2016 May; 127(3):455-62. PubMed ID: 26830091
[TBL] [Abstract][Full Text] [Related]
18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
19. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
20. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
